Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts
暂无分享,去创建一个
Iris Z. Uras | U. Jäger | M. Béné | R. Moriggl | K. Sotlar | P. Valent | M. Pfeilstöcker | W. Sperr | U. Germing | R. Oberbauer | I. Uras | O. Hermine | R. Stauder | G. Büsche | W. Füreder | I. Theurl | H. Horny | K. Geissler | P. Bettelheim | J. Schwaller
[1] P. Valent,et al. Anemia at older age: etiologies, clinical implications, and management. , 2018, Blood.
[2] S. Verstovsek,et al. Bone marrow findings in blast phase of polycythemia vera , 2018, Annals of Hematology.
[3] E. Solary,et al. The severe phenotype of Diamond-Blackfan anemia is modulated by heat shock protein 70. , 2017, Blood advances.
[4] D. Colomer,et al. Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia , 2017, British journal of haematology.
[5] Tetsuhiro Tanaka,et al. Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease. , 2017, Kidney international.
[6] B. Ebert,et al. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions , 2017, Oncotarget.
[7] J. Bennett,et al. New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types. , 2017, Leukemia research.
[8] Iris Z. Uras,et al. Cdk6 contributes to cytoskeletal stability in erythroid cells , 2017, Haematologica.
[9] M. Konopleva,et al. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. , 2017, Blood.
[10] L. Pleyer,et al. Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study , 2017, International journal of molecular sciences.
[11] A. Taher,et al. Anemia in the elderly: a consequence of aging? , 2017, Expert review of hematology.
[12] S. Rivella,et al. A Red Carpet for Iron Metabolism , 2017, Cell.
[13] K. Nagata,et al. Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib , 2016, Leukemia.
[14] Q. Wang,et al. Exome sequencing identifies highly recurrent somatic GATA2 and CEBPA mutations in acute erythroid leukemia , 2015, Leukemia.
[15] R. Day,et al. Erythropoietin Regulation by Angiotensin II. , 2017, Vitamins and hormones.
[16] D. Arber. Revisiting erythroleukemia , 2017, Current opinion in hematology.
[17] P. Fenaux,et al. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS). , 2017, Leukemia research.
[18] A. Shimamura. Aplastic anemia and clonal evolution: germ line and somatic genetics. , 2016, Hematology. American Society of Hematology. Education Program.
[19] S. Ghaffari,et al. Advances in understanding the mechanisms of erythropoiesis in homeostasis and disease , 2016, British journal of haematology.
[20] Takuhiro Yamaguchi,et al. Acute megakaryoblastic leukemia, unlike acute erythroid leukemia, predicts an unfavorable outcome after allogeneic HSCT. , 2016, Leukemia research.
[21] P. Greenberg,et al. Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta‐analysis , 2016, British journal of haematology.
[22] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[23] N. Taylor,et al. Metabolic regulation of hematopoietic stem cell commitment and erythroid differentiation , 2016, Current opinion in hematology.
[24] A. Ganser,et al. Impaired formation of erythroblastic islands is associated with erythroid failure and poor prognosis in a significant proportion of patients with myelodysplastic syndromes , 2016, Haematologica.
[25] Olivier Hermine,et al. Novel players in &bgr;-thalassemia dyserythropoiesis and new therapeutic strategies , 2016, Current opinion in hematology.
[26] Jodie L Babitt,et al. Hepcidin regulation in the anemia of inflammation , 2016, Current opinion in hematology.
[27] H. Yin,et al. Hepcidin: A Promising Therapeutic Target for Iron Disorders , 2016, Medicine.
[28] D. Birnbaum,et al. Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing , 2016, Leukemia.
[29] C. Pecquet,et al. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. , 2016, Blood.
[30] C. Camaschella,et al. Ineffective erythropoiesis and regulation of iron status in iron loading anaemias , 2016, British journal of haematology.
[31] F. Locatelli,et al. New Treatment Approaches for the Anemia of CKD. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[32] D. Arber,et al. Reclassifying myelodysplastic syndromes: what's where in the new WHO and why. , 2015, Hematology. American Society of Hematology. Education Program.
[33] A. Tefferi,et al. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors , 2015, Blood Cancer Journal.
[34] Tetsuhiro Tanaka,et al. How the Target Hemoglobin of Renal Anemia Should Be? , 2015, Nephron.
[35] B. Ebert,et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. , 2015, Blood.
[36] P. Faustino,et al. An overview of molecular basis of iron metabolism regulation and the associated pathologies. , 2015, Biochimica et biophysica acta.
[37] W. Winkelmayer,et al. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[38] D. Wojchowski,et al. Emerging EPO and EPO receptor regulators and signal transducers. , 2015, Blood.
[39] W. Jelkmann. The ESA scenario gets complex: from biosimilar epoetins to activin traps. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[40] M. Loken,et al. Assessment of erythroid dysplasia by “Difference from normal” in routine clinical flow cytometry workup , 2014, Cytometry. Part B, Clinical cytometry.
[41] M. Béné,et al. Identification of CAR As a Novel Mediator of Erythroid Differentiation and Migration That Is Specifically Downregulated in Erythropoietic Progenitor Cells in Patients with MDS , 2014 .
[42] Isaure Chauvot de Beauchêne,et al. HSP70 sequestration by free α-globin promotes ineffective erythropoiesis in β-thalassaemia , 2014, Nature.
[43] M. Jerkeman,et al. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. , 2014, Blood.
[44] E. Nemeth,et al. Molecular liaisons between erythropoiesis and iron metabolism. , 2014, Blood.
[45] T. Travison,et al. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point. , 2014, The journals of gerontology. Series A, Biological sciences and medical sciences.
[46] S. Rivella,et al. IDENTIFICATION OF ERYTHROFERRONE AS AN ERYTHROID REGULATOR OF IRON METABOLISM , 2014, Nature Genetics.
[47] F. Locatelli,et al. New treatment approaches in chronic kidney disease-associated anaemia , 2014, Expert opinion on biological therapy.
[48] A. Fricot,et al. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia , 2014, Nature Medicine.
[49] J. Palis. Primitive and definitive erythropoiesis in mammals , 2013, Front. Physiol..
[50] Daniel Hidalgo,et al. Erythropoiesis: from molecular pathways to system properties. , 2014, Advances in experimental medicine and biology.
[51] E. Hellström-Lindberg,et al. Erythropoiesis stimulating agents and other growth factors in low-risk MDS. , 2013, Best practice & research. Clinical haematology.
[52] C. Kovesdy. How Can Erythropoeitin‐Stimulating Agent Use be Reduced in Chronic Dialysis Patients? , 2013, Seminars in dialysis.
[53] J. Arlet,et al. HSP70 un régulateur de l’érythropoïèse qui détermine le destin des érythroblastes entre mort et différenciation , 2013 .
[54] J. Pérez-Ruixo,et al. Between subjects variability in haemoglobin and dose are not associated with the erythropoiesis‐stimulating agent used to treat anaemia in dialysis: a meta‐analysis , 2013, British journal of clinical pharmacology.
[55] A. Kohlmann,et al. Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics , 2013, Leukemia.
[56] O. Hermine,et al. [HSP70, an erythropoiesis regulator that determines the fate of erythroblasts between death and differentiation]. , 2013, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.
[57] V. Haase. Regulation of erythropoiesis by hypoxia-inducible factors. , 2013, Blood reviews.
[58] P. Valent. Low blood counts: immune mediated, idiopathic, or myelodysplasia. , 2012, Hematology. American Society of Hematology. Education Program.
[59] Juhi Jain,et al. Anemia and chronic kidney disease: making sense of the recent trials. , 2012, Reviews on recent clinical trials.
[60] Zhaoxiang Zhang,et al. Immunophenotypic analysis of erythroid dysplasia and its diagnostic application in myelodysplastic syndromes , 2012, Internal medicine journal.
[61] P. Vyas,et al. Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes. , 2012, Blood.
[62] Sa A. Wang,et al. Erythroid proliferations in myeloid neoplasms. , 2012, Human pathology.
[63] M. Michel,et al. Hemolytic anemia in adults: main causes and diagnostic procedures , 2012, Expert review of hematology.
[64] Harvey F Lodish,et al. From stem cell to red cell: regulation of erythropoiesis at multiple levels by multiple proteins, RNAs, and chromatin modifications. , 2011, Blood.
[65] M. Cazzola,et al. Identification of genomic aberrations associated with disease transformation by means of high‐resolution SNP array analysis in patients with myeloproliferative neoplasm , 2011, American journal of hematology.
[66] N. Milman. Postpartum anemia I: definition, prevalence, causes, and consequences , 2011, Annals of Hematology.
[67] S. Agarwal,et al. Polymeric IgA1 controls erythroblast proliferation and accelerates erythropoiesis recovery in anemia , 2011, Nature Medicine.
[68] S. Greenfield,et al. Clinical practice guidelines we can trust , 2011 .
[69] N. Raje,et al. Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. , 2010, Current opinion in molecular therapeutics.
[70] G. Guidi,et al. Advancements in anemias related to chronic conditions , 2010, Clinical chemistry and laboratory medicine.
[71] N. Madias,et al. The role of the renin-angiotensin system in the regulation of erythropoiesis. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[72] H. Schmid,et al. Erythropoiesis stimulating agents and anaemia of end-stage renal disease. , 2010, Cardiovascular & hematological agents in medicinal chemistry.
[73] Masayuki Yamamoto,et al. GATA factor switching during erythroid differentiation , 2010, Current opinion in hematology.
[74] M. Brines. The Therapeutic Potential of Erythropoiesis-Stimulating Agents for Tissue Protection: A Tale of Two Receptors , 2010, Blood Purification.
[75] S. Fiering,et al. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. , 2009, Blood.
[76] R. Garrick. A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease , 2010 .
[77] S. Solomon,et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. , 2009, The New England journal of medicine.
[78] P. Valent,et al. Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions , 2009, European journal of clinical investigation.
[79] G. Semenza,et al. Regulation of oxygen homeostasis by hypoxia-inducible factor 1. , 2009, Physiology.
[80] I. Macdougall,et al. Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications. , 2009, Advances in chronic kidney disease.
[81] E. Beutler,et al. Regulation of hepcidin and iron-overload disease. , 2009, Annual review of pathology.
[82] P. Valent. Anaemia of the elderly (AOE): does it exist and does it matter in clinical practice? , 2008, European journal of clinical investigation.
[83] N. Agarwal,et al. Erythropoietic agents and the elderly. , 2008, Seminars in hematology.
[84] N. Mohandas,et al. Erythroblastic islands: niches for erythropoiesis. , 2008, Blood.
[85] Thomas G. Smith,et al. The human side of hypoxia-inducible factor , 2008, British journal of haematology.
[86] Huiling Xue,et al. MicroRNA miR-24 inhibits erythropoiesis by targeting activin type I receptor ALK4. , 2008, Blood.
[87] Kim Si,et al. Transcriptional control of erythropoiesis: emerging mechanisms and principles. , 2007 .
[88] D. Cella,et al. Chronic Anemia and Fatigue in Elderly Patients: Results of a Randomized, Double‐Blind, Placebo‐Controlled, Crossover Exploratory Study with Epoetin Alfa , 2007, Journal of the American Geriatrics Society.
[89] A. Levchenko,et al. Negative Autoregulation by FAS Mediates Robust Fetal Erythropoiesis , 2007, PLoS biology.
[90] D. J. Veldhuisen,et al. Therapeutic potential of erythropoietin in cardiovascular disease: Erythropoiesis and beyond , 2007, Current heart failure reports.
[91] D. Steensma,et al. Anemia in the elderly: how should we define it, when does it matter, and what can be done? , 2007, Mayo Clinic proceedings.
[92] T. Haferlach,et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. , 2007, Leukemia research.
[93] Olivier Hermine,et al. Hsp70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1 , 2007, Nature.
[94] E. Bresnick,et al. Transcriptional control of erythropoiesis: emerging mechanisms and principles , 2007, Oncogene.
[95] W. Vainchenker,et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. , 2006, Blood.
[96] M. Socolovsky,et al. Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo. , 2006, Blood.
[97] H. Ehrenreich,et al. The Brain Erythropoietin System and its Potential for Therapeutic Exploitation in Brain Disease , 2006, Journal of neurosurgical anesthesiology.
[98] M. Cazzola,et al. Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome , 2006, Leukemia.
[99] Mary Cushman,et al. A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health Study. , 2005, Archives of internal medicine.
[100] M. Cazzola,et al. Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome , 2005, Leukemia.
[101] J. Prchal. Polycythemia vera and other primary polycythemias , 2005, Current opinion in hematology.
[102] Qin Huang. Pure erythroid leukemia. , 2009, Archives of pathology & laboratory medicine.
[103] M. Cazzola,et al. Flow Cytometry Evaluation of Erythroid Dysplasia in Patients with Myelodysplastic Syndrome. , 2004 .
[104] L. Ferrucci,et al. What Constitutes Normal Hemoglobin Concentration in Community‐Dwelling Disabled Older Women? , 2004, Journal of the American Geriatrics Society.
[105] U. Jäger,et al. Deficiency of pluripotent hemopoietic progenitor cells in myelodysplastic syndromes , 1988, Blut: Zeitschrift für die Gesamte Blutforschung.
[106] A. Donovan,et al. The molecular regulation of iron metabolism. , 2004, The hematology journal : the official journal of the European Haematology Association.
[107] I. Dybedal,et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life , 2003, British journal of haematology.
[108] Ruth Rimokh,et al. Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGFbeta family. , 2003, Experimental cell research.
[109] M. Labopin,et al. Hematopoietic stem cell transplantation for de novo erythroleukemia: a study of the European Group for Blood and Marrow Transplantation (EBMT). , 2002, Blood.
[110] S. Orkin,et al. Transcriptional regulation of erythropoiesis: an affair involving multiple partners , 2002, Oncogene.
[111] R. Carmel,et al. Anemia and aging: an overview of clinical, diagnostic and biological issues. , 2001, Blood reviews.
[112] B. Bain,et al. Acute erythremic myelosis (true erythroleukaemia): a variant of AML FAB-M6 , 2001, Journal of clinical pathology.
[113] J. S. San Miguel,et al. Recombinant human erythropoietin in the anaemia of multiple myeloma and non-Hodgkin's lymphoma. , 1998, Medical oncology.
[114] K. Lechner,et al. Interleukin-10 inhibits erythropoietin-independent growth of erythroid bursts in patients with polycythemia vera. , 1998, Blood.
[115] E. Fibach,et al. Improved method for diagnosis of polycythemia vera based on flow cytometric analysis of autonomous growth of erythroid precursors in liquid culture , 1997, American journal of hematology.
[116] A. Ullrich,et al. The adhesion molecule E-cadherin and a surface antigen recognized by the antibody 9C4 are selectively expressed on erythroid cells of defined maturational stages. , 1996, Leukemia.
[117] Rudolf Jaenisch,et al. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor , 1995, Cell.
[118] M. Simon. Transcription Factor GATA-1 and Erythroid Development , 1993, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[119] G. Keller,et al. Rescue of erythroid development in gene targeted GATA–1− mouse embryonic stem cells , 1992, Nature Genetics.
[120] H. Gisslinger,et al. Erythropoietin treatment of anemia associated with multiple myeloma. , 1990, The New England journal of medicine.
[121] D. Amato,et al. Erythroid burst formation in cultures of bone marrow and peripheral blood from patients with refractory anemia. , 1983, Acta haematologica.
[122] Y. Moriyama,et al. Studies on hematopoietic stem cells: XI. Lack of erythroid burst‐forming units (BFU‐E) in patients with aplastic anemia , 1979, American journal of hematology.
[123] M. Horányi. [Anemia in pregnancy]. , 1970, Orvosi hetilap.